Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study-Reference-Cited by-同舟云学术

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study

Published:2020-11-22 Issue:6 Volume:93 Page:3752-3760
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Chua Joel V.¹^ORCID,Ntem‐Mensah Afua¹,Abutaleb Ameer²,Husson Jennifer¹,Mutumbi Lydiah¹,Lam Ka Wing¹,Ghosh Alip¹,Romani Sara¹,Poonia Bhawna¹,Lee Sam³,Luz Pascual M.³,Frumkin Lyn R.⁴,Kottilil Shyamsundaran¹

Affiliation:

1. Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA

2. Division of Gastroenterology and Hepatology University of Maryland School of Medicine Baltimore Maryland USA

3. Cocrystal Pharma, Inc. Bothell Washington USA

4. Seattle Washington USA

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26652

Reference22 articles.

1. WHO. Global hepatitis report 2017. Geneva Switzerland: World Health Organization.

2. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

3. Shortening the duration of therapy for chronic hepatitis C infection

4. Are we nearing the end in the fight against hepatitis C?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis C Virus: Insights Into Its History, Treatment, Challenges, and Future Directions;Cureus;2023-08-22

2. Clinical Trials and Regulatory considerations of Antiviral agents;Viral Infections and Antiviral Therapies;2023

3. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections;Archives of Virology;2022-01-28